Statement from Roche on Phase II CLEMATIS Trial

28 Jun 2016 5:15 PM | Anonymous member (Administrator)

 This phase II study did not meet its primary and secondary endpoints on improvement in cognition and function

Roche statement:

LuMind statement1:

LuMind statement2:

Down Syndrome Medical Interest Group-USA

DSMIG-USA is a 501(3)(c) Organization

Contact Us

Site Design by:  Site to be Seen

Powered by Wild Apricot Membership Software